<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Canadian Pharmacy Blog &#187; Cancer</title>
	<atom:link href="http://www.canadiannetmall.com/blog/tag/cancer/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.canadiannetmall.com/blog</link>
	<description></description>
	<lastBuildDate>Sat, 07 May 2011 13:51:31 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.2</generator>
		<item>
		<title>Darbepoetin alfa for Anemia of Cancer</title>
		<link>http://www.canadiannetmall.com/blog/darbepoetin-alfa-for-anemia-of-cancer/</link>
		<comments>http://www.canadiannetmall.com/blog/darbepoetin-alfa-for-anemia-of-cancer/#comments</comments>
		<pubDate>Sun, 20 Feb 2011 07:15:30 +0000</pubDate>
		<dc:creator>Donald</dc:creator>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Anemia]]></category>
		<category><![CDATA[Darbepoetin alfa]]></category>

		<guid isPermaLink="false">http://www.canadiannetmall.com/blog/?p=4414</guid>
		<description><![CDATA[Interim data from a randomized, multi-center study indicate that darbepoetin alfa (Aranesp®, Amgen) is beneficial in correcting anemia in cancer patients who are not undergoing chemotherapy. The results were presented at the 45th annual meeting of the American Society of Hematology, from December 6-9, 2003 (Abstract No. 1816). The hemoglobin counts at the baseline examination [...]]]></description>
		<wfw:commentRss>http://www.canadiannetmall.com/blog/darbepoetin-alfa-for-anemia-of-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ADHD Drug Linked to Cancer?</title>
		<link>http://www.canadiannetmall.com/blog/adhd-drug-linked-to-cancer/</link>
		<comments>http://www.canadiannetmall.com/blog/adhd-drug-linked-to-cancer/#comments</comments>
		<pubDate>Sat, 02 Oct 2010 06:12:32 +0000</pubDate>
		<dc:creator>Donald</dc:creator>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[ADHD Drug]]></category>

		<guid isPermaLink="false">http://www.canadiannetmall.com/blog/?p=3880</guid>
		<description><![CDATA[Methylphenidate (Ritalin®, Novartis) has been the most popular drug for treating attention-deficit problems for more than 50 years, but a small study has linked its use with a higher risk of cancer. Texas researchers found that after only three months, 12 treated children had a three-fold increase in chromosome abnormalities associated with increased cancer risk. [...]]]></description>
		<wfw:commentRss>http://www.canadiannetmall.com/blog/adhd-drug-linked-to-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Raloxifene (Evista): Reducing  Breast Cancer Risk In Postmenopausal Women</title>
		<link>http://www.canadiannetmall.com/blog/raloxifene-evista-reducing-breast-cancer-risk-in-postmenopausal-women/</link>
		<comments>http://www.canadiannetmall.com/blog/raloxifene-evista-reducing-breast-cancer-risk-in-postmenopausal-women/#comments</comments>
		<pubDate>Thu, 18 Mar 2010 20:49:29 +0000</pubDate>
		<dc:creator>Donald</dc:creator>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Evista]]></category>
		<category><![CDATA[Osteoporosis]]></category>
		<category><![CDATA[raloxifene]]></category>

		<guid isPermaLink="false">http://www.canadiannetmall.com/blog/?p=3256</guid>
		<description><![CDATA[The FDA has approved raloxifene HCl (Evista, Eli Lilly) for reducing the risk of invasive breast cancer in post-menopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer. As a selective estrogen receptor modulator (SERM), raloxifene may act by blocking estrogen receptors in the breast. In 1997, the FDA approved [...]]]></description>
		<wfw:commentRss>http://www.canadiannetmall.com/blog/raloxifene-evista-reducing-breast-cancer-risk-in-postmenopausal-women/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Labeling Changes Stronger Warnings Approved For Erythropoietic Agents</title>
		<link>http://www.canadiannetmall.com/blog/labeling-changes-stronger-warnings-approved-for-erythropoietic-agents/</link>
		<comments>http://www.canadiannetmall.com/blog/labeling-changes-stronger-warnings-approved-for-erythropoietic-agents/#comments</comments>
		<pubDate>Wed, 27 Jan 2010 15:06:26 +0000</pubDate>
		<dc:creator>Donald</dc:creator>
				<category><![CDATA[Drugs News]]></category>
		<category><![CDATA[Anemia]]></category>
		<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Erythropoietic Agents]]></category>
		<category><![CDATA[Kidney disease]]></category>

		<guid isPermaLink="false">http://www.canadiannetmall.com/blog/?p=2802</guid>
		<description><![CDATA[The FDA has approved revised boxed warnings and safety-related product labeling changes for erythropoiesis-stimulating agents (ESAs), which treat certain types of anemia. ESAs are a bio-engineered version of a protein made in the kidneys that stimulates bone marrow to produce more red blood cells. A sampling of the new statements addresses the following: • Aranesp, [...]]]></description>
		<wfw:commentRss>http://www.canadiannetmall.com/blog/labeling-changes-stronger-warnings-approved-for-erythropoietic-agents/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Preventing Genital Warts With Gardasil in Males</title>
		<link>http://www.canadiannetmall.com/blog/preventing-genital-warts-with-gardasil-in-males/</link>
		<comments>http://www.canadiannetmall.com/blog/preventing-genital-warts-with-gardasil-in-males/#comments</comments>
		<pubDate>Wed, 09 Dec 2009 15:33:32 +0000</pubDate>
		<dc:creator>Donald</dc:creator>
				<category><![CDATA[Women's health]]></category>
		<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Gardasil]]></category>
		<category><![CDATA[Gardasil vaccine]]></category>
		<category><![CDATA[HPV]]></category>
		<category><![CDATA[papillomavirus]]></category>

		<guid isPermaLink="false">http://www.canadiannetmall.com/blog/?p=2545</guid>
		<description><![CDATA[Merck&#8217;s Gardasil vaccine is now indicated for the prevention of genital warts (condyloma acuminata) caused by human papillomavirus (HPV) types 6 and 11 in boys and men 9 through 26 years of age. Gardasil is currently approved for use in girls and women 9 through 26 years of age for preventing cervical, vulvar, and vaginal [...]]]></description>
		<wfw:commentRss>http://www.canadiannetmall.com/blog/preventing-genital-warts-with-gardasil-in-males/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

